• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

具有抗耐甲氧西林金黄色葡萄球菌(MRSA)活性的硝呋齐特衍生物对 Caco-2 细胞的细胞毒性。

Caco-2 cells cytotoxicity of nifuroxazide derivatives with potential activity against Methicillin-resistant Staphylococcus aureus (MRSA).

机构信息

Pharmaceutical Sciences Faculty, Pharmacy Department, University of São Paulo, Av. Prof. Lineu Prestes, 580, bl. 13, Cidade Universitária, 05508-900 São Paulo, SP, Brazil.

出版信息

Toxicol In Vitro. 2012 Apr;26(3):535-40. doi: 10.1016/j.tiv.2012.01.018. Epub 2012 Jan 21.

DOI:10.1016/j.tiv.2012.01.018
PMID:22285235
Abstract

It is important to determine the toxicity of compounds and co-solvents that are used in cell monolayer permeability studies to increase confidence in the results obtained from these in vitro experiments. This study was designed to evaluate the cytotoxicity of new nifuroxazide derivatives with potential activity against Methicillin-resistant Staphylococcus aureus (MRSA) in Caco-2 cells to select analogues for further in vitro permeability analyses. In this study, nitrofurantoin and nifuroxazide, in addition to 6 furanic and 6 thiophenic nifuroxazide derivatives were tested at 2, 4, 6, 8 and 10 μg/mL. In vitro cytotoxicity assays were performed according to the MTT (methyl tetrazolium) assay protocol described in ISO 10993-5. The viability of treated Caco-2 cells was greater than 83% for all tested nitrofurantoin concentrations, while those treated with nifuroxazide at 2, 4 and 6 μg/mL had viabilities greater than 70%. Treatment with the nifuroxazide analogues resulted in viability values greater than 70% at 2 and 4 μg/mL with the exception of the thiophenic methyl-substituted derivative, which resulted in cell viabilities below 70% at all tested concentrations. Caco-2 cells demonstrated reasonable viability for all nifuroxazide derivatives, except the thiophenic methyl-substituted compound. The former were selected for further permeability studies using Caco-2 cells.

摘要

确定用于细胞单层渗透性研究的化合物和共溶剂的毒性对于增加对这些体外实验结果的信心非常重要。本研究旨在评估具有抗耐甲氧西林金黄色葡萄球菌(MRSA)活性的新型硝呋太尔衍生物在 Caco-2 细胞中的细胞毒性,以选择用于进一步体外渗透性分析的类似物。在这项研究中,除了 6 个呋喃和 6 个噻吩硝呋太尔衍生物外,还在 2、4、6、8 和 10μg/mL 下测试了硝呋太因和硝呋太尔。根据 ISO 10993-5 中描述的 MTT(甲基噻唑基四唑)测定方案进行体外细胞毒性测定。用所有测试的硝呋太因浓度处理的 Caco-2 细胞的存活率均大于 83%,而用 2、4 和 6μg/mL 的硝呋太尔处理的细胞的存活率大于 70%。除噻吩甲基取代衍生物外,用硝呋太尔类似物处理时,在 2 和 4μg/mL 时的存活率大于 70%,而噻吩甲基取代衍生物在所有测试浓度下的细胞存活率均低于 70%。除噻吩甲基取代化合物外,Caco-2 细胞对所有硝呋太尔衍生物均表现出合理的活力。选择这些化合物进行进一步的 Caco-2 细胞渗透性研究。

相似文献

1
Caco-2 cells cytotoxicity of nifuroxazide derivatives with potential activity against Methicillin-resistant Staphylococcus aureus (MRSA).具有抗耐甲氧西林金黄色葡萄球菌(MRSA)活性的硝呋齐特衍生物对 Caco-2 细胞的细胞毒性。
Toxicol In Vitro. 2012 Apr;26(3):535-40. doi: 10.1016/j.tiv.2012.01.018. Epub 2012 Jan 21.
2
Caco-2 cells permeability evaluation of nifuroxazide derivatives with potential activity against methicillin-resistant Staphylococcus aureus (MRSA).对具有抗耐甲氧西林金黄色葡萄球菌(MRSA)潜在活性的硝呋柳胺衍生物进行Caco-2细胞渗透性评估。
Drug Dev Ind Pharm. 2015;41(7):1066-72. doi: 10.3109/03639045.2014.925919. Epub 2014 Jun 11.
3
A new class of nifuroxazide analogues: synthesis of 5-nitrothiophene derivatives with antimicrobial activity against multidrug-resistant Staphylococcus aureus.一类新型的硝呋太尔类似物:具有抗多重耐药金黄色葡萄球菌抗菌活性的5-硝基噻吩衍生物的合成。
Bioorg Med Chem. 2007 Jun 15;15(12):4229-36. doi: 10.1016/j.bmc.2007.03.068. Epub 2007 Mar 25.
4
Design, synthesis, antimicrobial activity and molecular modeling studies of novel benzofuroxan derivatives against Staphylococcus aureus.新型苯并呋咱衍生物对金黄色葡萄球菌的设计、合成、抗菌活性及分子模拟研究
Bioorg Med Chem. 2009 Apr 15;17(8):3028-36. doi: 10.1016/j.bmc.2009.03.011. Epub 2009 Mar 13.
5
Organ-targeted mutagenicity of nitrofurantoin in Big Blue transgenic mice.呋喃妥因在大蓝转基因小鼠中的器官靶向致突变性。
Mutagenesis. 2006 Sep;21(5):305-11. doi: 10.1093/mutage/gel036. Epub 2006 Aug 8.
6
Anti-methicillin-resistant Staphylococcus aureus (MRSA) activity of MC21-B, an antibacterial compound produced by the marine bacterium Pseudoalteromonas phenolica O-BC30T.海洋细菌酚假交替单胞菌O-BC30T产生的抗菌化合物MC21-B对耐甲氧西林金黄色葡萄球菌(MRSA)的活性
Int J Antimicrob Agents. 2009 Aug;34(2):131-5. doi: 10.1016/j.ijantimicag.2009.02.009. Epub 2009 Mar 28.
7
The synthesis of phenylalanine-derived C5-substituted rhodanines and their activity against selected methicillin-resistant Staphylococcus aureus (MRSA) strains.苯丙氨酸衍生的 C5 取代的罗丹宁的合成及其对选定耐甲氧西林金黄色葡萄球菌(MRSA)菌株的活性。
Eur J Med Chem. 2010 Dec;45(12):5827-32. doi: 10.1016/j.ejmech.2010.09.045. Epub 2010 Sep 25.
8
The antimicrobial activity of inert oligonuclear polypyridylruthenium(II) complexes against pathogenic bacteria, including MRSA.惰性寡核多吡啶钌(II)配合物对包括 MRSA 在内的致病菌的抗菌活性。
Dalton Trans. 2011 May 14;40(18):5032-8. doi: 10.1039/c1dt10250h. Epub 2011 Mar 28.
9
Synthesis and biological activity of nifuroxazide and analogs.硝呋太尔及其类似物的合成与生物活性
Boll Chim Farm. 1997 Mar;136(3):244-9.
10
Molecular modeling studies and in vitro bioactivity evaluation of a set of novel 5-nitro-heterocyclic derivatives as anti-T. cruzi agents.一组新型5-硝基杂环衍生物作为抗克氏锥虫药物的分子模拟研究及体外生物活性评价
Bioorg Med Chem. 2009 Apr 1;17(7):2673-9. doi: 10.1016/j.bmc.2009.02.056. Epub 2009 Mar 5.

引用本文的文献

1
Enhancing the Cellular Uptake and Antibacterial Activity of Rifampicin through Encapsulation in Mesoporous Silica Nanoparticles.通过包裹于介孔二氧化硅纳米颗粒中提高利福平的细胞摄取和抗菌活性
Nanomaterials (Basel). 2020 Apr 24;10(4):815. doi: 10.3390/nano10040815.
2
Synthesis of New Fluoro-Benzimidazole Derivatives as an Approach towards the Discovery of Novel Intestinal Antiseptic Drug Candidates.新型氟代苯并咪唑衍生物的合成:探索新型肠道抗菌候选药物的途径
Curr Pharm Des. 2017;23(15):2276-2286. doi: 10.2174/1381612822666161201150131.
3
Modulation of Drug Resistance in Staphylococcus aureus with Coumarin Derivatives.
香豆素衍生物对金黄色葡萄球菌耐药性的调节作用
Scientifica (Cairo). 2016;2016:6894758. doi: 10.1155/2016/6894758. Epub 2016 Apr 19.